297 related articles for article (PubMed ID: 18477158)
1. Histological and immunohistochemical evaluation of basal cell carcinoma following curettage and electrodessication.
Filho LL; de Oliveira de Avelar Alchorne A; Pereira GC; Lopes LR; de Carvalho TC
Int J Dermatol; 2008 Jun; 47(6):610-4. PubMed ID: 18477158
[TBL] [Abstract][Full Text] [Related]
2. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation.
Rodriguez-Vigil T; Vázquez-López F; Perez-Oliva N
J Am Acad Dermatol; 2007 Jan; 56(1):91-5. PubMed ID: 17190625
[TBL] [Abstract][Full Text] [Related]
3. Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma.
Fan YS; Carr RA; Sanders DS; Smith AP; Lazar AJ; Calonje E
Histopathology; 2007 Jul; 51(1):80-6. PubMed ID: 17593083
[TBL] [Abstract][Full Text] [Related]
4. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma.
Kuijpers DI; Thissen MR; Berretty PJ; Ideler FH; Nelemans PJ; Neumann MH
Dermatol Surg; 2007 May; 33(5):579-87. PubMed ID: 17451581
[TBL] [Abstract][Full Text] [Related]
5. Failure of curettage and electrodesiccation for removal of basal cell carcinoma.
Suhge d'Aubermont PC; Bennett RG
Arch Dermatol; 1984 Nov; 120(11):1456-60. PubMed ID: 6497413
[TBL] [Abstract][Full Text] [Related]
6. Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone.
Blixt E; Nelsen D; Stratman E
Dermatol Surg; 2013 May; 39(5):719-25. PubMed ID: 23379543
[TBL] [Abstract][Full Text] [Related]
7. Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: 5-year follow-up data.
Lawrence CM; Haniffa M; Dahl MG
Br J Dermatol; 2009 Mar; 160(3):573-80. PubMed ID: 19210500
[TBL] [Abstract][Full Text] [Related]
8. Management of basal cell carcinoma by surveyed dermatologists in Scotland.
Gudi V; Ormerod AD; Dawn G; Green C; MacKie RM; Douglas WS; Gupta G;
Clin Exp Dermatol; 2006 Sep; 31(5):648-52. PubMed ID: 16901303
[TBL] [Abstract][Full Text] [Related]
9. Prospective trial of curettage and cryosurgery in the management of non-facial, superficial, and minimally invasive basal and squamous cell carcinoma.
Peikert JM
Int J Dermatol; 2011 Sep; 50(9):1135-8. PubMed ID: 22126880
[TBL] [Abstract][Full Text] [Related]
10. Curettage-electrodesiccation treatment of basal cell carcinomas.
Kopf AW; Bart RS; Schrager D; Lazar M; Popkin GL
Arch Dermatol; 1977 Apr; 113(4):439-43. PubMed ID: 848972
[TBL] [Abstract][Full Text] [Related]
11. Factors contributing to incomplete excision of nonmelanoma skin cancer by Australian general practitioners.
Hansen C; Wilkinson D; Hansen M; Soyer HP
Arch Dermatol; 2009 Nov; 145(11):1253-60. PubMed ID: 19917954
[TBL] [Abstract][Full Text] [Related]
12. The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas.
Shah SM; Konnikov N; Duncan LM; Tannous ZS
Lasers Surg Med; 2009 Aug; 41(6):417-22. PubMed ID: 19588534
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up.
Christensen E; Skogvoll E; Viset T; Warloe T; Sundstrøm S
J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):58-66. PubMed ID: 18803580
[TBL] [Abstract][Full Text] [Related]
14. Dense inflammation does not mask residual primary basal cell carcinoma during Mohs micrographic surgery.
Katz KH; Helm KF; Billingsley EM; Maloney ME
J Am Acad Dermatol; 2001 Aug; 45(2):231-8. PubMed ID: 11464184
[TBL] [Abstract][Full Text] [Related]
15. CD10 expression in trichoepithelioma and basal cell carcinoma.
Pham TT; Selim MA; Burchette JL; Madden J; Turner J; Herman C
J Cutan Pathol; 2006 Feb; 33(2):123-8. PubMed ID: 16420307
[TBL] [Abstract][Full Text] [Related]
16. Perianal and genital basal cell carcinoma: A clinicopathologic review of 51 cases.
Gibson GE; Ahmed I
J Am Acad Dermatol; 2001 Jul; 45(1):68-71. PubMed ID: 11423837
[TBL] [Abstract][Full Text] [Related]
17. Does inflammation contribute to the eradication of basal cell carcinoma following curettage and electrodesiccation?
Spencer JM; Tannenbaum A; Sloan L; Amonette RA
Dermatol Surg; 1997 Aug; 23(8):625-30; discussion 630-1. PubMed ID: 9256908
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo.
Sandberg C; Halldin CB; Ericson MB; Larkö O; Krogstad AL; Wennberg AM
Br J Dermatol; 2008 Nov; 159(5):1170-6. PubMed ID: 18717673
[TBL] [Abstract][Full Text] [Related]
19. Incidence of residual basal cell carcinoma in patients who appear tumor free after biopsy.
Holmkvist KA; Rogers GS; Dahl PR
J Am Acad Dermatol; 1999 Oct; 41(4):600-5. PubMed ID: 10495384
[TBL] [Abstract][Full Text] [Related]
20. Follow-up of basal cell carcinomas: an audit of current practice.
Mc Loone NM; Tolland J; Walsh M; Dolan OM
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):698-701. PubMed ID: 16836498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
